Drug intelligence / Profile preview

isoxsuprine + methylprednisolone

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination of isoxsuprine, a vasodilator that relaxes smooth muscle surrounding small blood vessels causing vasodilation, and methylprednisolone, a corticosteroid that reduces inflammation. Isoxsuprine is primarily used to treat problems resulting from poor blood circulation and has been used as a tocolytic agent to manage preterm labor. Methylprednisolone is used to treat various inflammatory conditions including asthma and rheumatoid arthritis. According to search results, this combination has been studied in clinical trials for multiple sclerosis treatment.

Targets

ADRB1 (β1)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on isoxsuprine + methylprednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoxsuprine + methylprednisolone.

Explore the full profile